Sorafenib in Elderly Patients With Metastatic Renal Cell Carcinoma (SERCC Study) Impact of Adverse Events Management in Elderly mRCC Patients Treated With Sorafenib

Trial Profile

Sorafenib in Elderly Patients With Metastatic Renal Cell Carcinoma (SERCC Study) Impact of Adverse Events Management in Elderly mRCC Patients Treated With Sorafenib

Discontinued
Phase of Trial: Phase II

Latest Information Update: 01 Apr 2016

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Renal cancer
  • Focus Therapeutic Use
  • Acronyms SERCC
  • Most Recent Events

    • 05 Oct 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 17 Mar 2012 New source identified and integrated (EudraCT2010-019726-14; European Clinical Trials Database)
    • 30 Apr 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top